Bulletin Updates

Revenue Is Growing, But Operating Quality Decides The Winners – 10 Aug 2026

Aug 10, 2026

Profit Outruns Revenue

Bayer CropScience Limited: Unaudited results approved/published. Revenue fell 4.2%, but PBT rose 20.0% and PAT 15.4%.

Nitin Spinners Limited records unaudited results approved; investor presentation released. Improved yarn realisations and demand lifted revenue while margins expanded.

At Garware Hi-Tech Films Limited, the disclosed gate is unaudited standalone and consolidated results published. Revenue rose 28.4%, while PBT rose 59.9% and PAT 59.8%.

Ellenbarrie Industrial Gases Limited places the item at Q1 FY27 results published. Revenue and EBITDA grew, while the much faster PAT rise also reflects lower finance cost.

Ultramarine & Pigments Limited: Unaudited standalone and consolidated results approved. Revenue rose sharply, but profit grew roughly twice as fast.

At Pasupati Acrylon Limited, the disclosed gate is unaudited standalone results approved. Revenue rose modestly while PBT increased more than fifteen-fold.

J.G. Chemicals Limited: Unaudited consolidated results approved and expanded in an investor presentation. Profit outpaced revenue while the supplied material does not quantify price, volume and feedstock effects separately.

Turnarounds and Recoveries

M.M. Rubber Company Limited places the item at unaudited standalone results published. The company moved from loss to profit, but the small result extract gives no causal narrative.

I G Petrochemicals Limited records quarterly presentation reports sharp profit recovery. Core earnings swung positive, while management attribution is not decomposed into price, volume and feedstock effects.

At Hindustan Organic Chemicals Limited, the disclosed gate is Q1 FY27 unaudited results reported profit from continuing operations. Profit turned positive despite a steep revenue fall, but the filing does not disclose the price, volume, cost or one-off bridge.

Sadhana Nitro Chem Limited places the item at unaudited consolidated results approved. Profitability improved despite lower sales, but the group was loss-making.

Growth—with a Catch

Cosmo First Limited reports unaudited consolidated quarterly results published. Rapid revenue growth outpaced earnings growth.

Kanpur Plastipack Limited: Q1 FY27 results and operating data published. Income and margins rose even as core FIBC output fell and net debt increased.

Aether Industries Limited reports Q1 FY27 results reported growth; expansion spending was. Margins improved and working-capital intensity fell, but inventory was a stated operational priority.

At Shaily Engineering Plastics Limited, the disclosed gate is unaudited results and presentation published. Overall growth masks a sharp contraction in the consumer segment.

Earnings Quality Under the Lens

PIX Transmissions Limited records unaudited consolidated results published. Operating revenue grew strongly, but reported profit growth cannot be read as purely operating.

Fine Organic Industries Limited places the item at unaudited results reported higher revenue and profit; a property/inventory insurance settlement affected the period. Operating growth is evident, but year-on-year profit comparison includes different business-interruption/insurance items.

Aarti Industries Limited records Q1 FY27 results and management commentary published. Headline profit surged even as sequential volume fell and part of EBITDA came from inventory and currency effects.

Rishiroop Limited: Unaudited Q1 FY27 results approved. Core revenue grew strongly, but reported profit includes a substantial non-operating fair-value gain.

Mixed Signals and Strategic Shifts

Thirumalai Chemicals Limited reports Q1 FY27 investor presentation reports stronger standalone performance but was consolidated loss. Indian profitability turned positive even as consolidated PAT was negative and standalone revenue fell.

IOL Chemicals and Pharmaceuticals Limited reports FY26 annual results reported stronger revenue, EBITDA and profit. The company became less dependent on Ibuprofen as earnings improved, but its annual report does not isolate each product's profit contribution.

The full story is for subscribers. Log in to read it, or start a free trial.
Log in Start a free trial »